Pfizer Secures Early Patient Access In UK For Eczema Drug Abrocitinib
Company Expects To File For Approval Within Next Few Months
The UK is allowing certain patients with severe atopic dermatitis to be treated with Pfizer’s yet-to-be-approved abrocitinib, which is under review in several countries.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.